Effect of Moxonidine on the Uveoscleral Outflow: Role of α₂-Adrenoceptors or I₁ Imidazoline Receptors

REFERENCES

• Bing C, King P, Pickavance L, et al. The effect of moxonidine on feeding and body fat in obese Zucker rats: Role of hypothalamic NPY neurons. Br J Pharmacol 1999; 127: 35–42
   PubMedGoogle Scholar
• Farsang C, Kapocsi J. Imidazoline receptors: From discovery to antihypertensive therapy (facts and doubts). Brain Res Bull 1999; 49(5)317–331
   PubMedGoogle Scholar
• Bousquet P. Imidazoline receptors: From basic concept to recent developments. J Cardiovasc Pharmacol 1995; 26(Suppl. 2)S1–S6
   PubMedGoogle Scholar
• Bousquet P, Greney H, Bennai F, Feldman J, Stutzman J, Belcourt A, Dontenwill M. Imidazoline receptors and cardiovascular regulations: A statement. NY Acad Sci 1995; 763: 526–530
   PubMedGoogle Scholar
• Ernsberger P, Graves M E, Graff L M, Zakieh N, Nguyen P. I1 imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann NY Acad Sci 1995; 763: 22–42
   PubMedGoogle Scholar
• Campell W R, Potter D E. Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics. J Ocular Pharmacol 1994; 10(1)393–402
   PubMedGoogle Scholar
• Ogidigben M J, Potter D E. Central imidazoline (I(1)) receptors modulate aqueous hydrodynamics. Curr Eye Res 2001; 22(5)358–366
   PubMed Web of Science ®Google Scholar
• Campell W R, Potter D E. Centrally mediated ocular hypotension: Potential role of imidazoline receptors. Ann NY Sci 1995; 12: 763463–763485
   Google Scholar
• Ogidigben M J, Chu T C, Potter D E. Naphazoline-induced suppression of aqueous humor pressure and flow: Involvement of central and peripheral a2/i1 receptors. Exp Eye Res 2001; 72: 331–339
   PubMedGoogle Scholar
• Ogdigben M J, Chu T C, Potter D E. Ocular actions of moxonidine: A possible role for imidazoline receptors. J Pharmacol Ther 1994; 269(3)897–904
   PubMedGoogle Scholar
• Burke J, Khaiamb A, Shan T, Runde E, Padillo E, Manlapaz C, Wheeler L. Adrenergic and imidazoline receptor-mediated responses to UK-14,304–18 (brimonidine) in rabbits and monkeys. Ann NY Acad Sci 1995; 12(763)78–95
   Google Scholar
• Misiuk-Hojlo M, Szalinski M, Merwid-Lad A, Trocha M, Piesniewska M. Effect of rilmenidine on intraocular pressure in rabbits, interaction with efaroxan and rauwolscine. Klin Oczna 2004; 106(1–2)7–10
   PubMedGoogle Scholar
• Chu T C, Wong W, Gluchowski C, Hughes B W, Potter D E. Rilmenidine-induced ocular hypotension: Role of imidazoline1 and alpha 2 receptors. Curr Eye Res 1996; 15(9)943–950
   PubMed Web of Science ®Google Scholar
• Rouwayda E A, Ahmed M, Jolanta G, Suhayla M D. Imidazoline receptors but not α 2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment. J Pharmacol Exp Ther 2004; 310: 446–451
   PubMedGoogle Scholar
• Chu T C, Ogidigben M J, Potter D E. Oxymetazoline: Potential mechanisms of inhibitory effects on aqueous humor dynamics. Pharmacology 1996; 53(4)259–290
   PubMedGoogle Scholar
• Toris C B, Camras C B, Yablonski M E. Effect of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514–1517
   PubMed Web of Science ®Google Scholar
• Wang R F, Lee P Y, Taniguchi T, et al. Effect of oxymetazoline on aqueous humor dynamics and ocular blood flow in monkeys and rabbits. 1993; 111(4)535–538
   Google Scholar
• Katz L J. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127: 20–26
   PubMed Web of Science ®Google Scholar
• Simmons S T, Earl M L. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on β -blockers. Ophthalmology 2002; 109(2)307–314
   PubMed Web of Science ®Google Scholar
• Reitsamer H A, Posey M, Kiel J W. Effects of a topical a2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res 2006; 82: 405–415
   PubMedGoogle Scholar
• Mushtaq B, Sardar J, Matthews T D. A paradoxical ocular effect of brimonidine. Am J Ophthalmol 2003; 135: 102–103
   PubMedGoogle Scholar
• Erdogan H, Toker I, Arici M K, Aygen A, Topalkara A. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol 2003; 47: 473–478
   PubMedGoogle Scholar
• Stewart W C, Day D G, Stewart J A, Schuhr J, Latham K E. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631–635
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J. The Scandinavian Latanoprost Study Group. Effect on intraocular pressure and side effects of 0.005% latanoprost once daily, evening, and morning. A comparison with timolol. Ophthalmology 1995; 102: 1743–1752
   PubMed Web of Science ®Google Scholar
• Serle J B. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996; 41(Suppl 1)39–47
   PubMed Web of Science ®Google Scholar
• Lee D A, Gornbein J A. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001; 10: 220–226
   PubMed Web of Science ®Google Scholar
• Brookes Z S, Kaufman S. Effects of atrial natriuretic peptide on the extrasplenic microvasculature and lymphatics in the rat. in vivo. J Physiol 2005; 565(1)269–277
   PubMedGoogle Scholar
• Suguro K, Toris C B, Pederson J E. Uveoscleral outflow following in the monkey eye using a fluorescent tracer. Invest Ophthalmol Vis Sci 1985; 26(6)810–815
   PubMedGoogle Scholar
• Kaufman P L, Gabelt B T. Alpha-2-adrenergic effects on aqueous humor dynamics. J Glaucoma 1995; 4: 8–14
   Google Scholar
• Ogidigben M J, Chu T C, Potter D E. Naphazoline-induced neuroendocrine changes: Increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes. Pharmacology 2002; 65(3)155–161
   PubMedGoogle Scholar
• Toris C B, Gregerson D S, Pedeson J E. Uveoscleral outflow using different-sized fluorescent tracers in normal and inflamed eyes. Exp Eye Res 1987; 45(4)525–532
   PubMedGoogle Scholar
• Kim T W, Lindsey J D, Aihara M, Anthony T L, Weinreb R N. Intraocular distribution of 70 kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci 2002; 43: 1809–1816
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Sardar J, Matthews T D. A paradoxical ocular effect of brimonidine. Am J Ophthalmol 2003; 135: 102–103
   PubMedGoogle Scholar
• Toris C B, Camras C B, Yablonski M E. Effect of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514–1517
   PubMed Web of Science ®Google Scholar
• Liu J H, Dacus A C, Bartels S P. Adrenergic mechanism in circadian elevation of intraocular pressure in rabbits. Invest Ophthalmol Vis Sci 1991; 32: 2178–2183
   PubMed Web of Science ®Google Scholar
• Liu J H, Dacus A C, Bartels S P. Thyrotropin releasing hormone increases intraocular pressure. Mechanism of action. Invest Ophthalmol Vis Sci 1989; 30: 2200–2208
   PubMedGoogle Scholar
• Smith B R, Murray D L, Leopold I H. Influence of topically applied prazosin on the intraocular pressure of experimental animals. Arch Ophthalmol 1979; 97: 1933–1936
   PubMed Web of Science ®Google Scholar
• Kiuchi Y, Yoshitomi T, Gregory D S. Do α -adrenergic receptors participate in control of the circadian rhythm of IOP?. Invest Ophthalmol Vis Sci 1992; 33: 3183–3194
   Google Scholar
• Nishimura K, Kuwayama Y, Matsugi T, Sun N, Shirasawa E. Selective suppression by bunazosin of alpha-adrenergic agonist evoked elevation of intraocular pressure in sympathectomized rabbit eyes. Invest Ophthalmol Vis Sci 1993; 34: 1761–1766
   PubMed Web of Science ®Google Scholar
• Fairbanks C A, Wilcox G L. Moxonidine, a selective α2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J Pharmacol Exp Ther 1999; 290(1)403–412
   PubMedGoogle Scholar
• Bylund D B, Iversen L J, Matulka W J, Chacko D M. Characterization of alpha-2d adrenergic receptor subtypes in bovine ocular tissue homogenates. J Pharmacol Exp Ther 1997; 281: 1171
   PubMedGoogle Scholar
• Chao H M, Osborne N N. Topically applied clonidine protects the rat retina from ischaemia /reperfusion by stimulating α 2-adrenoceptors and not by an action on imidazoline receptors. Brain Res 2001; 904: 126–136
   PubMed Web of Science ®Google Scholar
• Osborne N N, DeSantis L, Bae J H, et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res 1999; 69: 331–3342
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Jian K, Takamatsu M, Okada K, Mukai S, Tsumamoto Y, Mishima H K. Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma. Jpn J Ophthalmol 2003; 47: 526–528
   PubMedGoogle Scholar
• Zhan G L, Toris C B, Camras C B, Wang Y L, Yablonski M E. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. J Ocul Pharmacol Ther 1998; 14: 217–228
   PubMed Web of Science ®Google Scholar